Pump performance boosts pilot plant efficiency
Wanner Engineering Hydra-Cell G10 seal-less pump selected by Axium Process
In designing for a range of applications, Axium had to ensure that the performance of its pilot plant was not only accurate but also flexible. As a major dynamic component in the plant, the performance of the pump would be particularly critical.
To meet these requirements the company chose the Hydra-Cell G10, a seal-less pump manufactured by Wanner Engineering in Hampshire, UK.
‘We chose the Hydra-Cell pump as we needed a pump that was able to give us a positive flow but operate at a range of pressures by using a variable speed drive or inverter, enabling us to run tests under different conditions for a variety of customer trials,’ said projects manager Steve Birkin.
‘As we use the plant for nanofiltration as well as reverse osmosis, the ability to operate at 15 bar to 60 bar is essential. We also needed stainless steel wetted parts and as pulse-free an operation as we could get.’
The Hydra-Cell offers smooth delivery and low pulsation, with the pumping action achieved through the sequential flexing of three hydraulically balanced diaphragms. The diaphragms also isolate liquid media from the drive end of the pump, allowing it to handle many different types of hot or cold liquid including acids, caustics, thin non-lubricants, slurries and liquids containing abrasive solids.
You may also like
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months